List view / Grid view
CRISPR has transformed gene editing, but still presents challenges in hard-to-transfect cells, such as pluripotent stem cells and primary cells.1 The key to obtaining successful transfection in these cells lies in innovative workflows. Here Georges Müller, CEO and cofounder of SEED Biosciences, shares his perspective on why focusing on editing…
Researchers find how antibiotic treatments influence the microbiota, providing new strategies for preventing antibiotic-induced damage.
Tune in to this episode where we discuss the opportunities CRISPR/Cas technology offers to revolutionise drug discovery.
Researchers have developed the world’s first animal model with A-to-G mtDNA edits achieved using engineered TALEDs.
AcrlC8 and AcrlC9 prevent the CRISPR-Cas3 machine from binding to its DNA target site, providing a safer way to engineer the genome.
Learn more about Euretos computational disease model and how it predicts many of the known drug targets for RA.
Researchers observed many quantifiable differences between diseased cells made from affected children and their gene-edited cells.
Anthrobots derived from human tracheal cells could perform therapeutic work without initiating an immune response.
In this interview, Anne Neville, Director at Microbiotica, elaborates on the significance of the Microbiotica Culture Collection (MCC) and Microbiotica Reference Genome Database (MRGD), which are fundamental to the development of live biotherapeutic medicines.
Researchers pinpoint connections of risk variants with microglia functions that are important for Alzheimer’s disease (AD).
New study reveals how pneumonia cells become resistant to penicillin through evolutionary gateway.
Researchers have found that targeting chimeras with click-release proteolysis activates specific molecules that target cancer cells without harming health cells.
This ebook outlines Euretos’ approach to target discovery and indication expansion. Whilst also discussing data-driven target selection.
Some individuals may experience more severe symptoms when infected with the same virus compared to others. The reasons behind this variability are not yet fully understood. While viral factors, such as differences in the virus strain, do play a role, they cannot account for the diverse responses observed among individuals…
Researchers are actively seeking to unravel the intricacies of gene expression regulation throughout the various stages of the P. falciparum lifecycle.
